Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rebecca Fransson

Showing results (21-30 of 23) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 23 results.
ACS Chemical Biology|December 15, 2015
Azacyclic FTY720 Analogues That Limit Nutrient Transporter Expression but Lack S1P Receptor Activity and Negative Chronotropic Effects Offer a Novel and Effective Strategy to Kill Cancer Cells in VivoBin Chen, Saurabh G Roy, Ryan J McMonigle, et al.
British Journal of Clinical Pharmacology|June 28, 2021
Characterisation of pharmacokinetics, safety and tolerability in a first-in-human study for AZD8154, a novel inhaled selective PI3Kγδ dual inhibitor targeting airway inflammatory diseaseMuhammad Waqas Sadiq, Sara Asimus, Maria G Belvisi, et al.
Journal of Medicinal Chemistry|June 3, 2021
Discovery of AZD8154, a Dual PI3Kγδ Inhibitor for the Treatment of AsthmaMatthew W D Perry, Karin Björhall, Peter Bold, et al.
Pageof 3

Showing results (21-30 of 23) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 23 results.
ACS Chemical Biology|December 15, 2015
Azacyclic FTY720 Analogues That Limit Nutrient Transporter Expression but Lack S1P Receptor Activity and Negative Chronotropic Effects Offer a Novel and Effective Strategy to Kill Cancer Cells in VivoBin Chen, Saurabh G Roy, Ryan J McMonigle, et al.
British Journal of Clinical Pharmacology|June 28, 2021
Characterisation of pharmacokinetics, safety and tolerability in a first-in-human study for AZD8154, a novel inhaled selective PI3Kγδ dual inhibitor targeting airway inflammatory diseaseMuhammad Waqas Sadiq, Sara Asimus, Maria G Belvisi, et al.
Journal of Medicinal Chemistry|June 3, 2021
Discovery of AZD8154, a Dual PI3Kγδ Inhibitor for the Treatment of AsthmaMatthew W D Perry, Karin Björhall, Peter Bold, et al.
Pageof 3